

# Pharmaceutical Contract Manufacturing (PCM) Global Market – Forecast To 2030

<https://marketpublishers.com/r/PFEC64837977EN.html>

Date: September 2023

Pages: 458

Price: US\$ 4,950.00 (Single User License)

ID: PFEC64837977EN

## Abstracts

Global pharmaceutical markets are experiencing rapid growth and are projected to continue evolving in the coming years, particularly in the areas of research and development, manufacturing, and formulation. This growth can be attributed to various factors, including the increasing global population, a rise in chronic diseases such as infectious diseases, oncology, and cardiovascular disorders, as well as a significant increase in healthcare expenditures. Additionally, the pharmaceutical industry is witnessing a surge in collaborations, mergers, and acquisitions, further driving its expansion. To keep up with this growing demand and to address various challenges, many pharmaceutical companies are turning to contract manufacturing organizations (CMOs). These companies rely on CMOs for their manufacturing needs, as they may lack well-equipped facilities, advanced technologies, or high containment capabilities. Even when they possess the necessary facilities, they may outsource production to CMOs to save time and have a backup manufacturing option. This increasing trend of outsourcing manufacturing to CMOs is beneficial for both pharmaceutical companies and the service providers. It allows pharmaceutical companies to focus on their core competencies while leaving the manufacturing responsibilities to specialized CMOs. This trend is favoring contract manufacturing service providers and is expected to increase the share in the pharmaceutical manufacturing market. Contract pharmaceutical manufacturing services are mainly focused on the manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF).

According to IQ4I analysis, the pharmaceutical contract manufacturing (PCM) global market is expected to grow at a mid single digit CAGR from 2023 to 2030 to reach \$100,102.8 million by 2030. The factors such as increased trend of outsourcing and high uptake of small molecules drugs across diverse therapeutics are driving the pharmaceutical contract manufacturing global market. Whereas, patent expiration and

increasing adoption of 505(b)(2) pathway of small molecules drugs, advanced technologies in API and FDF manufacturing, increasing R&D expenditures and Capacity and Capability Expansion in advanced Highly Potent APIs and Complex Molecules platforms are providing immense opportunities to the market. However, contamination of pharmaceutical products (API and FDF), pricing pressure for pharmaceutical contract manufacturing, requirement of highly skilled technicians, increasing biologics approvals and adoption in disease management, stringent regulatory policies, and environmental concerns are some of the factors that are hindering pharmaceutical contract manufacturing global market growth.

The pharmaceutical contract manufacturing global market is mainly segmented based on product, phase, application, and geography. The pharmaceutical contract manufacturing market based on product is segmented into API manufacturing and FDF manufacturing. API manufacturing segment held the largest revenue in 2023 and is expected to grow at a mid single digit CAGR from 2023 to 2030. The FDF manufacturing segment is expected to grow at a mid single digit CAGR from 2023 to 2030.

The API manufacturing global market based on product type is sub-segmented into Branded API manufacturing and Generic API manufacturing. The Branded API manufacturing segment accounted for the largest revenue in 2023 and is expected to grow at a mid single digit CAGR from 2023 to 2030. Generic API manufacturing segment is expected to grow at a high single digit CAGR from 2023 to 2030.

The FDF manufacturing global market based on dosage form is further classified into solid dosage form, injectable dosage form, and semi-solid liquid and gaseous dosage form. Solid dosage form segment accounted for the largest revenue in 2023 and is expected to grow at a mid single digit CAGR from 2023 to 2030. The injectable dosage form is expected to grow at a double digit CAGR from 2023 to 2030. Among semi-solid, liquid, and gaseous dosage form, semisolids segment accounted for the largest revenue of \$XX million in 2023 owing to the increased usage of semisolids such as creams, lotions and gels due to increase in skin related diseases, and changing climatic conditions followed by liquid forms with \$XX million and gaseous forms with \$XX million in 2023. The solid dosage form market is further classified into tablets, capsules, and others such as powders and granules. Among these, tablets segment generated the largest revenue of \$XX million in 2023 owing to its ease of formulation techniques, manufacturing, and ease of administration to all the age groups, whereas capsules segment generated the revenue of \$XX million and other segment such as powder and granules generated the revenue of \$XX million in 2023.

Pharmaceutical contract manufacturing global market based on phase is segmented into commercial manufacturing and clinical manufacturing. Commercial manufacturing segment contributed to the highest revenue in 2023 and is expected to grow at a mid single digit CAGR from 2023 to 2030. Whereas, clinical manufacturing is expected to grow at a mid single digit CAGR from 2023 to 2030.

The pharmaceutical contract manufacturing market based on therapeutic applications is segmented into infectious diseases, cardiovascular diseases, oncology, central nervous system, pulmonary diseases, gastrointestinal diseases, endocrine diseases, metabolic diseases, genitourinary diseases, musculoskeletal diseases, and others (eye, ENT, dental, nephrology, hepatology, post-operative pain, dermatology and others). Among these applications, the infectious disease segment accounted for the largest revenue in 2023 and is expected to grow at a mid single digit CAGR from 2023 to 2030. The oncology division is expected to grow at a high single digit CAGR from 2023 to 2030.

The pharmaceutical contract manufacturing market based on region is classified into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, and Others), and the Rest of the World (Brazil, Rest of Latin America and Middle East & others). North America accounts for the largest revenue of in 2023 and is expected to grow at a mid single digit CAGR from 2023 to 2030 due to growing pharma R&D expenditure, increasing development of new drugs over the time, increasing approval of generics, presence of number of API manufacturing facilities for all regulated drug products, increasing scope of highly potent drugs, government support to expand the domestic pharmaceutical manufacturing facilities, rise in the patient pool with various types of chronic disorders, increasing strategic partnerships among pharma companies & contract manufacturers and launch of advanced CDMO services.

The Asia-Pacific region is expected to grow at a high single digit CAGR from 2023 to 2030. The factors such as increasing generic pharmaceuticals, number of pharma companies with a strong network of manufacturing facilities (For instance, India is home for more than 3,000 pharma companies with a strong network of over 10,500 manufacturing facilities), increasing outsourcing with number of CMO's and expanding manufacturing facilities (Europe has outsourced most of its productions to India and China to restrain labor costs and energy expenditure), increasing development of new pharma drugs, increasing government investment to support the pharma industry (For instance, in June 2021, Government announced an additional outlay of \$26,578.3 million for the pharmaceutical PLI scheme in 13 key sectors such as active

pharmaceutical ingredients, drug intermediaries and key starting materials), increasing disease population, raising investment by the companies to expand their capabilities are driving the pharmaceutical contract manufacturing market in the region.

Some of the major players are AbbVie Inc. (U.S.), Asymchem Laboratories (Tianjin) (China), Cambrex Corporation (U.S.), Curia (U.S.), Delpharm (France), Lonza Group (Switzerland), Porton Pharma Solutions Ltd (China), Recipharm (Sweden), Thermo Fisher Scientific (U.S.) and WuXi AppTec (China).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

#### North America

U.S.

Rest of North America

#### Europe

Germany

France

Italy

Rest of Europe

#### Asia-Pacific

China

India

Japan

Rest of APAC

#### Rest of the World (RoW)

Brazil

Rest of Latin America

Middle East and Others

## Contents

### 1 EXECUTIVE SUMMARY

### 2 INTRODUCTION

#### 2.1 KEY TAKEAWAYS

#### 2.2 SCOPE OF THE REPORT

#### 2.3 REPORT DESCRIPTION

#### 2.4 MARKETS COVERED

#### 2.5 STAKEHOLDERS

#### 2.6 RESEARCH METHODOLOGY

##### 2.6.1 MARKET SIZE ESTIMATION

##### 2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION

##### 2.6.3 SECONDARY SOURCES

##### 2.6.4 PRIMARY SOURCES

##### 2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES

##### 2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES

##### 2.6.7 ASSUMPTIONS

### 3 MARKET ANALYSIS

#### 3.1 INTRODUCTION

#### 3.2 MARKET SEGMENTATION

#### 3.3 FACTORS INFLUENCING MARKET

##### 3.3.1 DRIVERS AND OPPORTUNITIES

###### 3.3.1.1 Increased trend of outsourcing

###### 3.3.1.2 High uptake of small molecules across diverse therapeutics

###### 3.3.1.3 Patent expiration and increasing adoption of 505(b)(2) pathway of small molecules drugs

###### 3.3.1.4 Increasing r&d expenditures

###### 3.3.1.5 Capacity and capability expansion in advanced highly potent apis and complex molecules platforms

###### 3.3.1.6 Advanced technologies in api and fdf manufacturing

##### 3.3.2 RESTRAINTS AND THREATS

###### 3.3.2.1 Contamination in the manufacturing process

###### 3.3.2.2 Requirement of highly skilled technicians

###### 3.3.2.3 Adoption of biologics in disease management and increasing regulatory

approvals

3.3.2.4 Stringent regulatory requirements

3.4 REGULATORY AFFAIRS

3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION

3.4.1.1 ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM

3.4.1.2 ISO 14644-1 CLEAN ROOM STANDARDS

3.4.2 U.S.

3.4.3 CANADA

3.4.4 MEXICO

3.4.5 EUROPE

3.4.6 JAPAN

3.4.7 CHINA

3.4.8 INDIA

3.4.9 AUSTRALIA

3.4.10 SOUTH KOREA

3.4.11 LATIN AMERICA

3.4.12 MIDDLE EAST

3.5 PORTER'S FIVE FORCE ANALYSIS

3.5.1 THREAT OF NEW ENTRANTS

3.5.2 THREAT OF SUBSTITUTES

3.5.3 BARGAINING POWER OF SUPPLIERS

3.5.4 BARGAINING POWER OF BUYERS

3.5.5 COMPETITIVE RIVALRY

3.6 SUPPLY CHAIN ANALYSIS

3.7 MARKET SHARE ANALYSIS

3.7.1 PHARMA CONTRACT MANUFACTURING GLOBAL MARKET  
SHARE ANALYSIS

3.7.2 MARKET SHARE ANALYSIS OF API MANUFACTURING BY MAJOR  
PLAYERS

3.7.3 MARKET SHARE ANALYSIS OF FDF MANUFACTURING BY MAJOR  
PLAYERS

3.8 TECHNOLOGICAL ADVANCEMENTS

3.8.1 INTRODUCTION

3.8.2 ADVANCED TECHNOLOGIES FOR API MANUFACTURING

3.8.3 ADVANCED TECHNOLOGIES FOR FDF MANUFACTURING

3.9 DIFFERENTIATED CAPABILITIES

3.9.1 HPAPI

3.9.2 CONTINUOUS FLOW MANUFACTURING

3.9.3 CRYOGENIC MANUFACTURING PROCESS

- 3.10 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING MARKET
- 3.11 PATENT EXPIRY AND ANDA APPROVALS
- 3.12 DRUG MASTER FILING (DMF)
- 3.13 API PRICING
- 3.14 COST OF MANUFACTURING FACILITY
- 3.15 FDA APPROVED API MANUFACTURING UNITS
- 3.16 FDA APPROVAL DRUGS WITH TYPE OF DOSAGE FORM
- 3.17 DEALS IN PHARMACEUTICAL COMPANIES AND CONTRACT MANUFACTURERS
- 3.18 ACQUISITION
- 3.19 EXPANSION
- 3.20 COLLABORATION AND INVESTMENT
- 3.21 GLOBAL PHARMACEUTICAL API CMO PRODUCTION VOLUME
- 3.22 CHINA V/S INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
  - 3.22.1 INDIA
  - 3.22.2 CHINA
- 3.23 PHARMACEUTICAL CONTRACT MANUFACTURERS REVENUE AND CAPABILITIES TABLE

#### **4 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET,**

##### BASED ON PRODUCT

- 4.1 INTRODUCTION
- 4.2 API MANUFACTURING
  - 4.2.1 BRANDED API MANUFACTURING
  - 4.2.2 GENERIC API MANUFACTURING
- 4.3 FINISHED DOSAGE FORM (FDF) MANUFACTURING
  - 4.3.1 SOLID DOSAGE FORMS
    - 4.3.1.1 Tablets
    - 4.3.1.2 Capsules
    - 4.3.1.3 Other solid dosage forms (granules and powders)
  - 4.3.2 INJECTABLES DOSAGE FORMS
  - 4.3.3 SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS
    - 4.3.3.1 Semisolids
    - 4.3.3.2 Liquids
    - 4.3.3.3 Gaseous

#### **5 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BASED**



## **ON PHASE**

- 5.1 INTRODUCTION
- 5.2 CLINICAL MANUFACTURING
- 5.3 COMMERCIAL MANUFACTURING

## **6 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BASED ON APPLICATION**

- 6.1 INTRODUCTION
- 6.2 ONCOLOGY
- 6.3 CENTRAL NERVOUS SYSTEM
- 6.4 CARDIOVASCULAR DISEASES
- 6.5 INFECTIOUS DISEASES
- 6.6 PULMONARY DISEASES
- 6.7 METABOLIC DISORDERS
- 6.8 GASTROINTESTINAL DISEASES
- 6.9 MUSCULOSKELETAL DISEASES
- 6.10 GENITOURINARY DISEASES
- 6.11 ENDOCRINE DISEASES
- 6.12 OTHER APPLICATIONS (ANESTHESIA, AUTOIMMUNE DISEASES, OPHTHALMOLOGY, DENTAL, PAIN MANAGEMENT, GYNAECOLOGY, DERMATOLOGY, AND ENT)

## **7 REGIONAL ANALYSIS**

- 7.1 INTRODUCTION
- 7.2 NORTH AMERICA
  - 7.2.1 U.S.
  - 7.2.2 REST OF NORTH AMERICA
- 7.3 EUROPE
  - 7.3.1 GERMANY
  - 7.3.2 FRANCE
  - 7.3.3 ITALY
  - 7.3.4 REST OF EUROPE
- 7.4 APAC
  - 7.4.1 CHINA
  - 7.4.2 INDIA
  - 7.4.3 JAPAN

- 7.4.4 REST OF APAC
- 7.5 ROW
  - 7.5.1 BRAZIL
  - 7.5.2 REST OF LATAM
  - 7.5.3 MIDDLE EAST & OTHERS

## **8 COMPETITIVE LANDSCAPE**

- 8.1 INTRODUCTION
- 8.2 EXPANSION
- 8.3 AGREEMENTS & COLLABORATION
- 8.4 ACQUISITION

## **9 MAJOR COMPANIES**

- 9.1 ABBVIE INC.
  - 9.1.1 OVERVIEW
  - 9.1.2 FINANCIALS
  - 9.1.3 PRODUCT PORTFOLIO
  - 9.1.4 KEY DEVELOPMENTS
  - 9.1.5 BUSINESS STRATEGY
  - 9.1.6 SWOT ANALYSIS
- 9.2 ASYMCHEM LABORATORIES (TIANJIN) CO., LTD
  - 9.2.1 OVERVIEW
  - 9.2.2 FINANCIALS
  - 9.2.3 SERVICE PORTFOLIO
  - 9.2.4 KEY DEVELOPMENTS
  - 9.2.5 BUSINESS STRATEGY
  - 9.2.6 SWOT ANALYSIS
- 9.3 CAMBREX CORPORATION
  - 9.3.1 OVERVIEW
  - 9.3.2 FINANCIALS
  - 9.3.3 PRODUCT PORTFOLIO
  - 9.3.4 KEY DEVELOPMENTS
  - 9.3.5 BUSINESS STRATEGY
  - 9.3.6 SWOT ANALYSIS
- 9.4 CURIA
  - 9.4.1 OVERVIEW
  - 9.4.2 FINANCIALS

- 9.4.3 SERVICE PORTFOLIO
- 9.4.4 KEY DEVELOPMENTS
- 9.4.5 BUSINESS STRATEGY
- 9.4.6 SWOT ANALYSIS
- 9.5 DELPHARM - DELRIV
  - 9.5.1 OVERVIEW
  - 9.5.2 FINANCIALS
  - 9.5.3 SERVICE PORTFOLIO
  - 9.5.4 KEY DEVELOPMENTS
  - 9.5.5 BUSINESS STRATEGY
  - 9.5.6 SWOT ANALYSIS
- 9.6 LONZA GROUP LTD
  - 9.6.1 OVERVIEW
  - 9.6.2 FINANCIALS
  - 9.6.3 SERVICES PORTFOLIO
  - 9.6.4 KEY DEVELOPMENTS
  - 9.6.5 BUSINESS STRATEGY
  - 9.6.6 SWOT ANALYSIS
- 9.7 PORTON PHARMA SOLUTIONS LTD
  - 9.7.1 OVERVIEW
  - 9.7.2 FINANCIALS
  - 9.7.3 SERVICE PORTFOLIO
  - 9.7.4 KEY DEVELOPMENTS
  - 9.7.5 BUSINESS STRATEGY
  - 9.7.6 SWOT ANALYSIS
- 9.8 RECIPHARM AB
  - 9.8.1 OVERVIEW
  - 9.8.2 FINANCIALS
  - 9.8.3 PRODUCT PORTFOLIO
  - 9.8.4 KEY DEVELOPMENTS
  - 9.8.5 BUSINESS STRATEGY
  - 9.8.6 SWOT ANALYSIS
- 9.9 THERMO FISHER SCIENTIFIC INC
  - 9.9.1 OVERVIEW
  - 9.9.2 FINANCIALS
  - 9.9.3 SERVICE PORTFOLIO
  - 9.9.4 KEY DEVELOPMENTS
  - 9.9.5 BUSINESS STRATEGY
  - 9.9.6 SWOT ANALYSIS

## 9.10 WUXI APPTEC CO., LTD.

### 9.10.1 OVERVIEW

### 9.10.2 FINANCIALS

### 9.10.3 SERVICE PORTFOLIO

### 9.10.4 KEY DEVELOPMENTS

### 9.10.5 BUSINESS STRATEGY

### 9.10.6 SWOT ANALYSIS

## List Of Tables

### LIST OF TABLES

TABLE 1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 2 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE, BASED ON MARKET, (2022-2030) (\$MN)

TABLE 3 PATENT EXPIRY OF SYNTHETIC API DRUGS, (2022 – 2024)

TABLE 4 ANDA APPROVALS: SMALL MOLECULES - GENERICS, (2020 – 2023)

TABLE 5 API PRICING OF MAJOR SMALL MOLECULES

TABLE 6 GLOBAL PHARMACEUTICALS API REVENUE (\$MN), AVERAGE SELLING PRICE (\$/KG) AND PRODUCTION IN TONS, BY APPLICATION (2023)

TABLE 7 GLOBAL PHARMACEUTICAL API PRODUCTION, BASED ON APPLICATION, (2022-2030) (TONS)

TABLE 8 GLOBAL SMALL MOLECULE API PRODUCTION, (2023 -2030) (METRIC TONS)

TABLE 9 GLOBAL PHARMACEUTICAL VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2023-2030) (MILLION LITRES)

TABLE 10 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BASED ON PRODUCT (2022-2030) (\$MN)

TABLE 11 API MANUFACTURING GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 12 API MANUFACTURING GLOBAL MARKET REVENUE, BASED ON CUSTOMER BASE, (2022-2030) (\$MN)

TABLE 13 BRANDED API MANUFACTURING GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 14 GENERIC API MANUFACTURING GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 15 FDF MANUFACTURING GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 16 FDF MANUFACTURING GLOBAL MARKET REVENUE, BASED ON DOSAGE FORM, (2022-2030) (\$MN)

TABLE 17 SOLID DOSAGE FORMS GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 18 INJECTABLES DOSAGE FORMS GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 19 SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 20 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BASED ON PHASE, (2022-2030) (\$MN)

TABLE 21 CLINICAL MANUFACTURING GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 22 COMMERCIAL MANUFACTURING GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 23 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2022-2030) (\$MN)

TABLE 24 ONCOLOGY PCM GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 25 CENTRAL NERVOUS SYSTEM PCM GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 26 CARDIOVASCULAR DISEASES PCM GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 27 INFECTIOUS DISEASES PCM GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 28 PULMONARY DISEASES PCM GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 29 METABOLIC DISEASES PCM GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 30 GASTROINTESTINAL DISEASES PCM GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 31 MUSCULOSKELETAL DISEASES PCM GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 32 GENITOURINARY DISEASES PCM GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 33 ENDOCRINE DISEASES PCM GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 34 OTHER APPLICATION PCM GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 35 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2030) (\$MN)

TABLE 36 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT, (2022-2030) (\$MN)

TABLE 37 NORTH AMERICA API MANUFACTURING MARKET REVENUE, BASED ON CUSTOMER BASE, (2022-2030) (\$MN)

TABLE 38 NORTH AMERICA FDF MANUFACTURING MARKET REVENUE, BASED ON DOSAGE FORM, (2022-2030) (\$MN)

TABLE 39 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING

MARKET REVENUE, BASED ON PHASE, (2022-2030) (\$MN)

TABLE 40 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION, (2022-2030) (\$MN)

TABLE 41 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON COUNTRY, (2022-2030) (\$MN)

TABLE 42 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT, (2022-2030) (\$MN)

TABLE 43 EUROPE API MANUFACTURING MARKET REVENUE, BASED ON CUSTOMER BASE, (2022-2030) (\$MN)

TABLE 44 EUROPE FDF MANUFACTURING MARKET REVENUE, BASED ON DOSAGE FORM, (2022-2030) (\$MN)

TABLE 45 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PHASE, (2022-2030) (\$MN)

TABLE 46 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION, (2022-2030) (\$MN)

TABLE 47 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON COUNTRY, (2022-2030) (\$MN)

TABLE 48 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT, (2022-2030) (\$MN)

TABLE 49 APAC API MANUFACTURING MARKET REVENUE, BASED ON CUSTOMER BASE, (2022-2030) (\$MN)

TABLE 50 APAC FDF MANUFACTURING MARKET REVENUE, BASED ON DOSAGE FORM, (2022-2030) (\$MN)

TABLE 51 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PHASE, (2022 - 2030) (\$MN)

TABLE 52 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION, (2022-2030) (\$MN)

TABLE 53 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON COUNTRY, (2022-2030) (\$MN)

TABLE 54 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT, (2022-2030) (\$MN)

TABLE 55 ROW API MANUFACTURING MARKET REVENUE, BASED ON CUSTOMER BASE, (2022-2030) (\$MN)

TABLE 56 ROW FDF MANUFACTURING MARKET REVENUE, BASED ON DOSAGE FORM, (2022-2030) (\$MN)

TABLE 57 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PHASE, (2022-2030) (\$MN)

TABLE 58 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION, (2022-2030) (\$MN)

TABLE 59 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON COUNTRY, (2022-2030) (\$MN)

TABLE 60 EXPANSION (2021-2023)

TABLE 61 AGREEMENT AND COLLABORATION (2021-2023)

TABLE 62 ACQUISITION (2021-2023)

TABLE 63 ABBVIE INC.: TOTAL REVENUE AND R&D EXPENSES, (2021-2023) (Q2)(\$MN)

TABLE 64 ABBVIE INC.: TOTAL REVENUE, BY SEGMENTS, (2021-2023) (Q2)(\$MN)

TABLE 65 ABBVIE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2021-2023) (Q2)(\$MN)

TABLE 66 LONZA GROUP: TOTAL REVENUE & R&D EXPENSES (2021 -2023) (Q2) (\$MN)

TABLE 67 LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2021 -2023) (Q2) (\$MN)

TABLE 68 LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2021 -2023) (Q2) (\$MN)

TABLE 69 THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE AND R&D EXPENSES (2021-2023) (Q2) (\$MN)

TABLE 70 THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY SEGMENT, (2021-2023) (Q2) (\$MN)

TABLE 71 THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY GEOGRAPHY (2021-2023) (Q2) (\$MN)

TABLE 72 WUXI APPTTEC CO., LTD.: TOTAL REVENUE AND R&D EXPENSES, (2021-2023) (Q2) (\$MN)

TABLE 73 WUXI APPTTEC CO., LTD.: TOTAL REVENUE, BY SEGMENTS, (2021-2023) (Q2) (\$MN)



## List Of Figures

### LIST OF FIGURES

FIGURE 1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BASED ON REGION (2023-2030) (\$MN)

FIGURE 2 RESEARCH METHODOLOGY: PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET

FIGURE 3 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH

FIGURE 4 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: FORECASTING MODEL

FIGURE 5 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 6 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SEGMENTATION

FIGURE 7 MARKET DYNAMICS

FIGURE 8 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: PORTER'S ANALYSIS

FIGURE 9 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: SUPPLY CHAIN ANALYSIS

FIGURE 10 PHARMA CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2023 (%)

FIGURE 11 API MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2023 (%)

FIGURE 12 FDF MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2023(%)

FIGURE 13 CONTRACT MANUFACTURING COMPANY CAPABILITIES

FIGURE 14 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE, BASED ON MARKET, 2023 (\$MN)

FIGURE 15 PATENT EXPIRY OF SMALL MOLECULES (2022-2024)

FIGURE 16 PATENT EXPIRY OF SYNTHETIC API DRUGS, BASED ON APPLICATION SHARE (2022-2024) (%)

FIGURE 17 ANDA APPROVALS OF SYNTHETIC API DRUGS, BASED ON APPLICATION SHARE (2020-2023) (%)

FIGURE 18 API DMF FILED BASED ON REGION AND COUNTRIES (NO'S) (2022 – 2023)

FIGURE 19 API DMF FILED, BASED ON COMPANY (2022 – 2023) (NO'S)

FIGURE 20 FDA APPROVED GLOBAL API MANUFACTURING LANDSCAPE

FIGURE 21 FDA APPROVED DRUGS AND FORMULATION TYPE (2021 – 2022)

FIGURE 22 PHARMACEUTICAL API PRODUCTION BY APPLICATION (2020), IN-HOUSE V/S CMO (2022 – 2029) (TONS) AND GLOBAL MANUFACTURING CAPACITIES (2023) (LITRES)

FIGURE 23 GLOBAL PHARMACEUTICAL API CMO PRODUCTION (2022 – 2029) (TONS), API CMO MARKET SHARE BY REGION (2023) (%)

FIGURE 24 INDIA V/S CHINA

FIGURE 25 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BASED ON PRODUCT (2023 V/S 2030) (%)

FIGURE 26 API MANUFACTURING GLOBAL MARKET SHARE, BASED ON CUSTOMER BASE (2023 V/S 2030) (%)

FIGURE 27 FDF MANUFACTURING GLOBAL MARKET SHARE, BASED ON DOSAGE FORM, (2023 V/S 2030) (%)

FIGURE 28 SOLID DOSAGE FORM CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BASED ON DOSAGE TYPE, (2023) (%)

FIGURE 29 SEMI-SOLID, LIQUID, AND GASEOUS DOSAGE FORM MANUFACTURING GLOBAL MARKET SHARE, BASED ON DOSAGE FORM, (2023) (%)

FIGURE 30 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BASED ON PHASE (2023 V/S 2030) (%)

FIGURE 31 COMMERCIAL MANUFACTURING GLOBAL MARKET SHARE, BASED ON REGION, (2023 V/S 2030) (%)

FIGURE 32 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BASED ON APPLICATION (2023 V/S 2030) (%)

FIGURE 33 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BASED ON REGION (2023-2030) (\$MN), CAGR (%)

FIGURE 34 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE BASED GEOGRAPHY (2023) (%)

FIGURE 35 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BASED ON PRODUCT (2023 V/S 2030) (%)

FIGURE 36 NORTH AMERICA API MANUFACTURING MARKET SHARE, BASED ON CUSTOMER BASE (2023 V/S 2030) (%)

FIGURE 37 NORTH AMERICA FINISHED DOSAGE FORM (FDF) MANUFACTURING MARKET SHARE, BASED DOSAGE FORM (2023 V/S 2030) (%)

FIGURE 38 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BASED ON PHASE (2023 V/S 2030) (%)

FIGURE 39 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BASED ON APPLICATION (2023 V/S 2030) (%)

FIGURE 40 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING

SHARE, BASED ON COUNTRY (2023 V/S 2030) (%)

FIGURE 41 U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 42 U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 V/S 2030) (\$MN)

FIGURE 43 REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 44 REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 V/S 2030) (\$MN)

FIGURE 45 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BASED ON PRODUCT (2023 V/S 2030) (%)

FIGURE 46 EUROPE API MANUFACTURING MARKET SHARE, BASED ON CUSTOMER PHASE (2023 V/S 2030) (%)

FIGURE 47 EUROPE FDF MANUFACTURING MARKET SHARE, BASED ON DOSAGE FORM (2023 V/S 2030) (%)

FIGURE 48 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BASED ON PHASE (2023 V/S 2030) (%)

FIGURE 49 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BASED ON APPLICATION (2023 V/S 2030) (%)

FIGURE 50 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BASED ON COUNTRY (2023 V/S 2030) (%)

FIGURE 51 GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 52 GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 VS 2030) (\$MN)

FIGURE 53 FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 54 FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 VS 2030) (\$MN)

FIGURE 55 ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 56 ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 VS 2030) (\$MN)

FIGURE 57 REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 58 REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 VS 2030) (\$MN)

FIGURE 59 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BASED ON PRODUCT (2023 V/S 2030) (%)

FIGURE 60 APAC API MANUFACTURING MARKET SHARE BASED ON CUSTOMER BASE (2023 V/S 2030) (%)

FIGURE 61 APAC FDF MANUFACTURING MARKET SHARE BASED ON DOSAGE FORM (2023 V/S 2030) (%)

FIGURE 62 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BASED ON PHASE (2023 VS 2030) (%)

FIGURE 63 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BASED ON APPLICATION (2023 VS 2030) (%)

FIGURE 64 APAC PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BASED ON COUNTRY (2023 V/S 2030) (%)

FIGURE 65 CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 66 CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 VS 2030) (\$MN)

FIGURE 67 INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 68 INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 VS 2030) (\$MN)

FIGURE 69 JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 70 JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 VS 2030) (\$MN)

FIGURE 71 REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 72 REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 VS 2030) (\$MN)

FIGURE 73 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BASED ON PRODUCT (2023 V/S 2030) (%)

FIGURE 74 ROW API MANUFACTURING MARKET SHARE BASED ON CUSTOMER BASE (2023 V/S 2030) (%)

FIGURE 75 ROW FDF MANUFACTURING MARKET SHARE BASED ON DOSAGE FORM (2023 V/S 2030) (%)

FIGURE 76 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BASED ON PHASE (2023 VS 2030) (%)

FIGURE 77 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BASED ON APPLICATION (2023 VS 2030) (%)

FIGURE 78 ROW PHARMACEUTICAL CONTRACT MANUFACTURING SHARE,

BASED ON COUNTRY (2023 V/S 2030) (%)

FIGURE 79 BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 80 BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 VS 2030) (\$MN)

FIGURE 81 REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 82 REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 VS 2030) (\$MN)

FIGURE 83 MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON PRODUCT (2023 V/S 2030) (\$MN)

FIGURE 84 MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BASED ON APPLICATION (2023 VS 2030) (\$MN)

FIGURE 85 KEY GROWTH STRATEGIES, (2021-2023)

FIGURE 86 SWOT: ABBVIE INC.

FIGURE 87 SWOT: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD

FIGURE 88 SWOT: CAMBREX CORPORATION

FIGURE 89 SWOT: CURIA

FIGURE 90 SWOT: DELPHARM

FIGURE 91 SWOT: LONZA GROUP

FIGURE 92 SWOT: PORTON PHARMA SOLUTIONS LTD

FIGURE 93 SWOT: RECIPHARM AB

FIGURE 94 SWOT: THERMO FISHER SCIENTIFIC

FIGURE 95 SWOT: WUXI APPTec (WUXI STA PHARMACEUTICALS LTD)

## I would like to order

Product name: Pharmaceutical Contract Manufacturing (PCM) Global Market – Forecast To 2030

Product link: <https://marketpublishers.com/r/PFEC64837977EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PFEC64837977EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970